11:55 AM
 | 
Nov 08, 2018
 |  BC Innovations  |  Emerging Company Profile

Abarceo: restoring beta cell function

Why Abarceo is targeting VDAC1 to treat Type II diabetes

Abarceo Pharma AB has identified VDAC1 as a key target in Type II diabetes, and is developing antibodies and small molecule inhibitors against the target as durable and disease-modifying treatments.

Standard first-line therapy for Type II diabetes is metformin, which works mainly by suppressing glucose production in the liver and is dosed once daily. The drug’s MOA is not fully understood but it likely acts on multiple targets, leading to side effects and poor patient compliance.

Other drugs on the market include insulin-sensitizing thiazolidinediones (TZDs), GLP-1 analogs, DPP-4 inhibitors and SGLT2 inhibitors, all of which require daily dosing, and none of which targets the underlying disease mechanism.

Abarceo, which spun...

Read the full 532 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >